Risk Factors for Vascular Dementia and Alzheimer Disease
TLDR
The vascular factors that might be responsible to cognitive decline in Alzheimer disease and vascular cognitive impairment are reviewed and the corresponding intervenvations that might prevent cognitive impairment as the authors age are reviewed.Abstract:
Alzheimer disease and vascular cognitive impairment are important causes of cognitive decline in the elderly. It has now been shown that vascular risk factors have measurable negative effects on the brain and are associated with cognitive impairment. We review vascular factors that might be responsible to cognitive decline in Alzheimer disease and vascular cognitive impairment and the corresponding intervenvations that might prevent cognitive impairment as we age.read more
Citations
More filters
Journal ArticleDOI
Vascular Contributions to Cognitive Impairment and Dementia A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Philip B. Gorelick,Angelo Scuteri,Sandra E. Black,Charles DeCarli,Steven M. Greenberg,Costantino Iadecola,Lenore J. Launer,Stéphane Laurent,Oscar L. Lopez,David L. Nyenhuis,Ronald C. Petersen,Julie A. Schneider,Christophe Tzourio,Donna K. Arnett,David A. Bennett,Helena C. Chui,Randall T. Higashida,Ruth Lindquist,Peter M. Nilsson,Gustavo C. Román,Frank W. Sellke,Sudha Seshadri +21 more
TL;DR: This scientific statement provides an overview of the evidence on vascular contributions to cognitive impairment and dementia and provides evidence that subcortical forms of VCI with white matter hyperintensities and small deep infarcts are common and risk markers for VCI are the same as traditional risk factors for stroke.
Journal ArticleDOI
Neurovascular mechanisms of Alzheimer's neurodegeneration
TL;DR: The neurovascular hypothesis of AD is proposed, suggesting that faulty clearance of amyloid beta peptide across the blood-brain barrier, aberrant angiogenesis and senescence of the cerebrovascular system could initiate Neurovascular uncoupling, vessel regression, brain hypoperfusion and neurov vascular inflammation.
Journal ArticleDOI
Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health initiative: A randomized trial
Sylvia Wassertheil-Smoller,Susan L. Hendrix,Marian C. Limacher,Gerardo Heiss,Charles Kooperberg,Alison E. Baird,Theodore A. Kotchen,J. David Curb,Henry R. Black,Jacques E. Rossouw,Aaron K. Aragaki,Monika M. Safford,Evan A. Stein,Somchai Laowattana,W. Jerry Mysiw +14 more
TL;DR: Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.
Journal ArticleDOI
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
TL;DR: Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease found NSAIDs offer some protection against the development of Alzheimer's Disease.
Journal ArticleDOI
The effects of tobacco smoke and nicotine on cognition and the brain.
TL;DR: The reviewed evidence suggests caution with the use of medicinal nicotine in pregnant mothers and older adults at risk for certain neurological disease, and the assessment of cognition-related genotypes to better understand the role of interactions between smoking/nicotine and variation in genotype in determining susceptibility to the neurotoxic effects of smoking and the putative beneficial effects of medicinal Nicotine.
References
More filters
Journal ArticleDOI
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
Garnet L. Anderson,Marian C. Limacher,Annlouise R. Assaf,Tamsen Bassford,Shirley A.A. Beresford,Henry R. Black,Denise E. Bonds,Robert L. Brunner,Robert G. Brzyski,Bette J. Caan,Rowan T. Chlebowski,J. David Curb,Margery Gass,Jennifer Hays,Gerardo Heiss,Susan L. Hendrix,Barbara V. Howard,Judith Hsia,F. Allan Hubbell,Rebecca D. Jackson,Karen C. Johnson,Howard L. Judd,Jane Morley Kotchen,Lewis H. Kuller,Andrea Z. LaCroix,Dorothy S. Lane,Robert Langer,Norman L. Lasser,Cora E. Lewis,JoAnn E. Manson,Karen L. Margolis,Judith K. Ockene,Mary Jo O'Sullivan,Lawrence S. Phillips,Ross L. Prentice,Cheryl Ritenbaugh,John A Robbins,Jacques E. Rossouw,Gloria E. Sarto,Marcia L. Stefanick,Linda Van Horn,Jean Wactawski-Wende,Robert B. Wallace,Sylvia Wassertheil-Smoller +43 more
TL;DR: The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
Journal ArticleDOI
Brain Infarction and the Clinical Expression of Alzheimer Disease: The Nun Study
David A. Snowdon,Lydia H. Greiner,James A. Mortimer,Kathryn P. Riley,Philip A. Greiner,William R. Markesbery +5 more
TL;DR: Findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD.
Journal ArticleDOI
Estrogen plus progestin and the risk of coronary heart disease
JoAnn E. Manson,Judith Hsia,Karen C. Johnson,Jacques E. Rossouw,Annlouise R. Assaf,Norman L. Lasser,Maurizio Trevisan,Henry R. Black,Susan R. Heckbert,Robert Detrano,Ora L. Strickland,Nathan D. Wong,John R. Crouse,Evan A. Stein,Mary Cushman +14 more
TL;DR: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.
Journal ArticleDOI
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Sally A. Shumaker,Claudine Legault,Stephen R. Rapp,Leon J. Thal,Robert B. Wallace,Judith K. Ockene,Susan L. Hendrix,Beverly N. Jones,Annlouise R. Assaf,Rebecca D. Jackson,Jane Morley Kotchen,Sylvia Wassertheil-Smoller,Jean Wactawski-Wende +12 more
TL;DR: Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older and did not prevent mild cognitive impairment in these women, supporting the conclusion that the risks of estrogen plus progESTin outweigh the benefits.
Journal ArticleDOI
Alzheimer's Disease and Parkinson's Disease
TL;DR: The genetics of these familial forms of Alzheimer's and Parkinson's disease are examined to improve understanding of the pathobiology of the more common, sporadic forms of the diseases.
Related Papers (5)
Vascular dementia Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*
Gustavo C. Román,Thomas K. Tatemichi,T. Erkinjuntti,Jeffrey L. Cummings,Joseph C. Masdeu,J. H. Garcia,L. Amaducci,J. M. Orgogozo,A. Brun,Albert Hofman,D. M. Moody,M. D. O’Brien,T. Yamaguchi,Jordan Grafman,B. P. Drayer,D. A. Bennett,Marc Fisher,J. Ogata,E. Kokmen,F. Bermejo,Philip A. Wolf,P. B. Gorelick,K. L. Bick,A. K. Pajeau,M. A. Bell,Charles DeCarli,A. Culebras,Amos D. Korczyn,J. Bogousslavsky,A. Hartmann,P. Scheinberg +30 more